000			02208 a2200637 4500
005			20250515202559.0
264		0	_c20100322
008			201003s 0 0 eng d
022			_a1538-8514
024	7		_a10.1158/1535-7163.MCT-09-0938 _2doi
040			_aNLM _beng _cNLM
100	1		_aWalton, Michael I
245	0	0	_aThe preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. _h[electronic resource]
260			_bMolecular cancer therapeutics _cJan 2010
300			_a89-100 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aBiomarkers, Tumor _xmetabolism
650	0	4	_aCamptothecin _xadministration & dosage
650	0	4	_aCell Death _xdrug effects
650	0	4	_aCell Line, Tumor
650	0	4	_aCheckpoint Kinase 1
650	0	4	_aDNA Damage
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDrug Synergism
650	0	4	_aG2 Phase _xdrug effects
650	0	4	_aHumans
650	0	4	_aIrinotecan
650	0	4	_aIsoquinolines _xadministration & dosage
650	0	4	_aMice
650	0	4	_aMice, Nude
650	0	4	_aMutagens _xtoxicity
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProtein Kinases _xmetabolism
650	0	4	_aPyrazines _xadministration & dosage
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_aGemcitabine
700	1		_aEve, Paul D
700	1		_aHayes, Angela
700	1		_aValenti, Melanie
700	1		_aDe Haven Brandon, Alexis
700	1		_aBox, Gary
700	1		_aBoxall, Kathy J
700	1		_aAherne, G Wynne
700	1		_aEccles, Suzanne A
700	1		_aRaynaud, Florence I
700	1		_aWilliams, David H
700	1		_aReader, John C
700	1		_aCollins, Ian
700	1		_aGarrett, Michelle D
773	0		_tMolecular cancer therapeutics _gvol. 9 _gno. 1 _gp. 89-100
856	4	0	_uhttps://doi.org/10.1158/1535-7163.MCT-09-0938 _zAvailable from publisher's website
999			_c19432891 _d19432891